WIPO MAGAZINE Gilead Targets Elimination of Hepatitis C

First Page		Document Content
Date: 2015-02-17 05:50:43 Patent Hepatitis C virus Hepatitis C Societal views on patents Pharmaceutical industry Law Thought Patent law Pharmaceutical sciences Gilead Sciences		WIPO MAGAZINE Gilead Targets Elimination of Hepatitis C Add to Reading List Source URL: www.wipo.int Download Document from Source Website File Size: 1,32 MB Share Document on Facebook

	Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study DocID: 1vngt - View Document
	PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno DocID: 1vlwz - View Document
	PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes    DocID: 1vjI2 - View Document
	Contact PD/PI: Braithwaite, Ronald Scott A. SPECIFIC AIMS Many persons with HIV have Hepatitis C (HCV) co-infection and consume alcohol.1,2 Now that highly effective and easily tolerated therapies for HCV are available, DocID: 1vbzY - View Document
	PRESS RELEASE AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection  TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C DocID: 1vais - View Document